Oncimmune Holdings
plc
("Oncimmune" or the "Company")
Additional contract win with
Top 10 Pharma Company
Oncimmune Holdings plc (AIM:
ONC.L), a leading autoantibody profiling company providing research
services to the pharmaceutical and biotechnology industry to enable
the delivery of precision medicine, is pleased to announce another
new contract win with a Top 10 Global Pharma Company.
Further to its announcement on 9
August 2024 of an agreement for a new contract with a major global
pharmaceutical company with a value of at least US$1.5M, Oncimmune
has now agreed a new project with another major pharmaceutical
company, with the contract value of US$0.7m. The contract is
with a customer for whom Oncimmune is already a preferred supplier
under a long-term master services agreement. The project
focuses on a rare immune related disease, an area in which
Oncimmune has considerable experience, and aims to identify
biomarkers related to disease or disease subtype, organ involvement
and clinical response. It will use an array of over 1,000
antigens run on Oncimmune's high-throughput, bead-based
system. Oncimmune will analyse over 500 samples, many of
which are already held by Oncimmune.
Martin Gouldstone, CEO of Oncimmune said:
"I
continue to be pleased with the commercial progress we are making,
especially in terms of the increasing scale of the projects we are
winning with major customers. Our recent wins show that our
strategy is working and I am confident that we are in a strong
position to meet our targets for FY24 and reach profitability in
FY25."
For
further information:
Oncimmune Holdings plc
contact@oncimmune.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash, Callum Davidson, Trisyia
Jamaludin (Corporate Finance)
Nigel Birks, Ondraya Swanson
(ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
This Announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation No. 596/2014 as
retained as part of UK law by virtue of the
European Union (Withdrawal) Act 2018 as amended ("EUWA") and as it may be
modified from time to time by or under domestic law including,
but not limited to, by the Market Abuse (Amendment) (EU Exit)
Regulations 2019/310). Upon the publication of this Announcement,
this inside information is now considered to be in the public
domain.
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the UK,
with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com